Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Long-term continuation study of subcutaneous mezagitamab in adults with chronic primary immune thrombocytopenia
2025-521692-31-00Phase 3Authorised
- Sponsor
- Takeda
- Start
- Dec 2025
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 20
01
Overview
Phase 3, open-label, single-arm trial of mezagitamab in chronic primary immune thrombocytopenia (ITP), sponsored by Takeda. Primary endpoints: Occurrence of treatment-emergent adverse events and serious treatment-emergent adverse events and Occurrence of TEAEs leading to permanent withdrawal of mezagitamab. Planned start Dec 2025; status: authorised.
02
Drugs
mezagitamab
03
Conditions
chronic primary immune thrombocytopenia (ITP)
Beyond the preview
Go deeper on 2025-521692-31-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2025-521692-31-00.